DiaMedica Therapeutics Inc DMAC:NASDAQ

Last Price$1.97NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22

Today's Change+0.07(3.68%)
Bid (Size)$1.97 (2)
Ask (Size)$2.00 (12)
Day Low / High$1.88 - 1.98
Volume80.7 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/12/2022

 

DiaMedica Therapeutics Inc ( NASDAQ )

Price: $1.97
Change: +0.07 (3.68%)
Volume: 80.7 K
4:00PM ET 8/12/2022
 
 

Hepion Pharmaceuticals Inc ( NASDAQ )

Price: $0.72
Change: -0.02 (2.55%)
Volume: 280.5 K
3:59PM ET 8/12/2022
 
 

Adamis Pharmaceuticals Corp ( NASDAQ )

Price: $0.33
Change: -0.02 (5.26%)
Volume: 1.9 M
4:00PM ET 8/12/2022
 
 

Avalo Therapeutics Inc ( NASDAQ )

Price: $5.78
Change: +0.33 (6.06%)
Volume: 177.7 K
4:00PM ET 8/12/2022
 
 

Ocuphire Pharma Inc ( NASDAQ )

Price: $2.54
Change: -0.25 (8.96%)
Volume: 161.2 K
4:00PM ET 8/12/2022
 

Read more news Recent News

Insider Buy: Diamedica Therapeutics
1:15PM ET 7/21/2022 MT Newswires

Thomas Von Koch, 10% Owner, on July 08, 2022, executed a purchase for 207,974 shares in Diamedica Therapeutics (DMAC) for $275,898. Following the Form 4...

Top Midday Decliners
2:14PM ET 7/07/2022 MT Newswires

DiaMedica Therapeutics (DMAC) said the US Food and Drug Administration placed a clinical hold on its phase 2/3 ReMEDy2 trial of its drug candidate DM199 to...

--Oppenheimer Downgrades DiaMedica Therapeutics to Market Perform From Outperform
12:56PM ET 7/07/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Lake Street Trims DiaMedica Therapeutics' Price Target to $8 From $14, Keeps Buy Rating
12:52PM ET 7/07/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionDiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN. View company web site for more details
Address2 Carlson Parkway
Minneapolis, Minnesota 55447
Phone+1.763.312.6755
Number of Employees9
President. Chief Executive Officer & DirectorRick John Pauls
Chief Financial Officer & SecretaryScott Kellen
Chief Medical OfficerKirsten Gruis
Chief Commercial OfficerDominic Cundari

Company Highlights

Price Open$1.89
Previous Close$1.90
52 Week Range$1.15 - 4.82
Market Capitalization$52.1 M
Shares Outstanding26.4 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/09/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.56
Beta vs. S&P 500N/A
Revenue$500.0 K
Net Profit MarginN/A
Return on Equity-35.66%

Analyst Ratings as of 07/06/2022

Buy
3
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset